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Hypertensive disorders of pregnancy (HDP) occur in almost 10% of gestations. These
women are known to have higher cardiovascular morbidity and mortality later in
life in comparison with parous controls who had normotensive pregnancies. Several
studies have demonstrated that women with preeclampsia present in a state of
segmental impaired myocardial function, biventricular chamber dysfunction, adverse
biventricular remodeling, and hypertrophy, a compromised hemodynamic state and
indirect echocardiographic signs of localized myocardial ischemia and fibrosis. These
cardiac functional and geometric changes are known to have strong predictive value
for cardiovascular disease in non-pregnant subjects. A “dose effect” response seems
to regulate this relationship with severe HDP, early-onset HDP, coexistence of fetal
growth disorders, and recurrence of HDP resulting in poorer cardiovascular measures.
The mechanism underlying the relationship between HDP in younger women and
cardiovascular disease later in life is unclear but could be explained by sharing of
pre-pregnancy cardiovascular risk factors or due to a direct impact of HDP on the
maternal cardiovascular system conferring a state of increased susceptibility to future
metabolic or hemodynamic insults. If so, the prevention of HDP itself would become
all the more urgent. Shortly after delivery, women who experienced HDP express an
increased risk of classic cardiovascular risk factors such as essential hypertension,
renal disease, abnormal lipid profile, and diabetes with higher frequency than controls.
Within one or two decades after delivery, this group of women are more likely
to experience premature cardiovascular events, such as symptomatic heart failure,
myocardial ischemia, and cerebral vascular disease. Although there is general agreement
that women who suffered from HDP should undertake early screening for cardiovascular
risk factors in order to allow for appropriate prevention, the exact timing and modality of
screening has not been standardized yet. Our findings suggest that prevention should
start as early as possible after delivery by making the women aware of their increased
cardiovascular risk and encouraging weight control, stop smoking, healthy diet, and daily
exercise which are well-established and cost-effective prevention strategies.
Keywords: preeclampsia, gestational hypertension, hypertensive disorders of pregnancy, essential hypertension,
cardiovascular disease, heart failure, coronary artery disease
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INTRODUCTION
Numerous epidemiological studies have proven the relationship
between hypertensive disorders in pregnancy (HDP) and
increased cardiovascular risk factors and diseases (CVD) later
in life (1, 2). This is not surprising as several studies already
demonstrated that women with preeclampsia (PE) present in
pregnancy a state of impaired myocardial contractility and
relaxation, biventricular systo-diastolic chamber dysfunction,
adverse biventricular remodeling and hypertrophy, an impaired
hemodynamic state, and indirect echocardiographic signs of
localized myocardial ischemia and fibrosis (3–5). The above
described structural and functional cardiovascular changes do
not completely reverse at 1 year postpartum notwithstanding
the unloading conditions and are known to be highly
predictive for future cardiovascular adverse outcome (3, 6).
Furthermore, clinical data has shown that the cardiopulmonary
complications already occur in 6% of severe PE and are
associated with increased maternal mortality (7). The American
Heart Association has already recognized PE as independent
risk factor for CVD and introduced this complication of
pregnancy in the algorithms for the evaluation of future
cardiovascular risk score (8). The physiopathology for this
additional CVD risk is still unknown with the existing literature
hypothesizing the possibility of pregnancy-induced CVD risk
vs. pre-conceptional susceptibility toward an increased risk of
CVD or both. The aim of this review is to elucidate the
association between HDP and future cardiovascular risk factors
and CVD. HDP include gestational hypertension (GH), PE
or eclampsia, chronic hypertension, and PE superimposed on
top of chronic hypertension. This review will focus on HDP
involving new-onset hypertension after 20 weeks’ gestation, but
other complications of pregnancy such as normotensive small for
gestational age or fetal growth restriction as well as normotensive
preterm birth, placental abruption, and stillbirth will not be
included. This review will focus on the future cardiovascular
health of these women, but other outcomes, such as renal failure,
diabetes, or other dysmetabolic conditions will not be examined.
SEARCH STRATEGY AND SELECTION OF
ARTICLES
A literature examination was accomplished to identify all
reports in the English language literature (Medline, National
Library of Medicine) published after 2000 until now as previous
meta-analysis showed that there were not suitable papers on
this topic from 1946 to 1999 (9). The search terms used were
“pre-eclampsia,” “gestational hypertension,” “hypertension
during pregnancy,” “hypertensive disorders of pregnancy,”
“long term outcomes,” “cardiovascular risk,” “cardiovascular
health,” “cardiovascular disease,” “essential hypertension,”
“peripheral artery disease,” “asymptomatic atherosclerosis,”
“diastolic dysfunction,” “heart failure,” “coronary artery
disease,” “cerebrovascular disease.” We excluded abstracts of
oral communications and posters of congresses even if available
on Medline. Furthermore, the bibliography of the selected
papers were dissected to further identify pertinent studies. The
combined set encompassed 230 articles which were reviewed,
and a total of 87 articles were considered appropriate for this
review. The relevant data were extracted from the full text of the
published papers.
RESULTS
The research yielded 59 prospective (3, 6, 10–66) and 28
retrospective studies (67–93) which were synthetically described
in Table 1. The number of women analyzed in each study ranged
from 58 to 1,072,330 in prospective studies and from 71 to
1,452,926 in retrospective ones. The year of pregnancy included
into the studies ranged from 1952 to 2017 in prospective studies
and from 1939 to 2016 in retrospective articles. The following
complications of pregnancy were included into the studies:
HDP, placental infarction and abruption, preterm delivery, low
birth weight offspring, small-for-gestational-age fetuses, fetal
growth restriction, stillbirth, gestational diabetes mellitus, and
pre-gestational diabetes mellitus. The interval between delivery
and cardiovascular risk assessment or between delivery and
cardiovascular event occurrence were assessed in the majority of
the studies, the median of follow up ranging from at least 7 weeks
post-partum tomore than 30 years after delivery. Themedian age
of the women at the assessment of CV risk or at the occurrence of
CV event ranged from 25 to 71 years in the different studies. The
following cardiovascular risks or events were differently assessed
in the numerous included studies: essential hypertension,
heart failure, coronary, cerebro-vascular and peripheral artery
disease, asymptomatic atherosclerosis, dyslipidemia, metabolic
syndrome, type II diabetes, and renal dysfunction.
The following outcomes will be analyzed in this review:
• Essential hypertension
• Peripheral artery disease
• Asymptomatic atherosclerosis
• Asymptomatic heart failure
• Heart failure
• Coronary artery disease
• Cerebrovascular disease.
DISCUSSION
Essential Hypertension
All authors who addressed the issue of the relationship
between HDP and future development of essential hypertension
unanimously found that women who developed HDP have
an increased risk of having high blood pressure later in life
(Table 1). There seems to be a “dose-dependent” effect of HDP
and future risk of developing chronic hypertension depending
on the severity of the hypertension in pregnancy, the onset of
the complication in pregnancy, the need of iatrogenic preterm
delivery, the association to fetal growth disorders and the
numbers of pregnancies complicated by HDP. In particular
Hauspurg et al. found that “HDP were associated with an aOR
of 1.86 (95%CI 1.37–2.52) of development hypertension at one
year with PE having an aOR of 2.35 (95%CI 1.63–3.41) whereas
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TABLE 1 | Studies included in this review.
References Demographic Design of the study Study population Year of pregnancy Complications of
pregnancy
Post-partum
follow-up time
in years
Age of the
women at the
assessment
in years
Cardiovascular
outcomes assessed
Kestenbaum et al. (10) North America
(USA)
Population-based cohort
study
N = 31,239 cases
N = 92902 controls
1987–1998 HPD 7.8 (mean) 36 (mean) Cardiovascular event
Sattar et al. (11) Europe (UK) Prospective case control N = 40 cases
N = 40 controls
1975–1985 PE 15–25 (range) 43 (median) Essential chronic
hypertension
Ray et al. (67) North America
(Canada)
Population-based
retrospective cohort study
N = 75380 cases
N = 950885 controls
1990–2004 PE, HDP, PA 8.7 (median) Age at
delivery28 (mean)
Age at first CV
event 38.3 (mean)
Coronary heart disease
Cerebro-vascular disease
Peripheral artery disease
Manten et al. (12) Europe
(Netherlands)
Prospective case control N = 256 cases
N = 53 controls
NA PE 0.82 (mean) cases
0.48 (mean)
controls
31 (mean) cases
33 (mean) controls
Essential chronic
hypertension
Cardiovascular risk
Berends et al. (13) Europe
(Netherlands)
Prospective case control N = 106 cases
N = 106 controls
1983–2004 PE and FGR 7.1 (median) NA Essential chronic
hypertension
Asymptomatic
atherosclerosis
Valensise et al. (3) Europe (Italy) Prospective longitudinal
case-control study
N = 107
N = 1119 controls
1999–2007 PE 1 34 (median) early
onset PE
32 (median) late
onset PE
32 (median)
controls
Essential chronic
hypertension
Cardiac dysfunction
and remodeling
Edlow et al. (14) North America
(USA)
Prospective case-control
study
N = 79 cases
N = 140 controls
2006 PE 0.5–1 (range) NA Essential chronic
hypertension
Haukkamaa et al. (15) Europe (Finland) Cross-sectional study N = 96 cases
N = 489 controls
NA HDP NA 55.1 (mean) Essential chronic
hypertension
Coronary heart disease
Asymptomatic
atherosclerosis
Lykke et al. (16) Europe
(Denmark)
Registry-based cohort study N = 782287 cases 1978–2007 HDP 14.6 (median) NA Essential chronic
hypertension
Coronary heart disease
Cerebrovascular disease
Heart failure
Peripheral artery disease
Cardiovascular risk
Magnussen et al. (17) Europe (Norway) Registry-based cohort study N = 15065 cases NA HDP 16.5 (median) NA Essential chronic
hypertension
Cardiovascular risk
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TABLE 1 | Continued
References Demographic Design of the study Study population Year of pregnancy Complications of
pregnancy
Post-partum
follow-up time
in years
Age of the
women at the
assessment
in years
Cardiovascular
outcomes assessed
Nijdam et al. (68) Europe
(Netherlands)
Retrospective case control N = 35 cases
N = 150 control
2000–2007 PE 2.9 (mean) NA Essential chronic
hypertension
Coronary heart disease
Cerebrovascular disease
Smith et al. (18) North America
(Canada)
Prospective cohort N = 70 cases
N = 70 control
NA PE 1 30.5 (mean) Cardiovascular risk
Canti et al. (19) South America
(Brazil)
Cross sectional N = 40 cases
N = 14 controls
NA PE 15.9 (mean) 39.2 (mean) Cardiovascular risk
Ben-Ami et al. (69) Asia (Israel) Retrospective case-control
study
N = 101 cases
N = 101 controls
NA HDP, PA, PD, SGA,
abortions
NA 43.3 (mean) cases
41.9 (mean)
controls
Essential chronic
hypertension
Coronary heart disease
Cerebrovascular disease
Peripheral artery disease
Cardiovascular event
Lykke et al. (70) Denmark Retrospective cohort study N = 782287 1978–2007 PD, SGA, HDP, PA
and stillbirth
14.8 (median) 41.6 (mean) Death from
cardiovascular causes
Mongraw-Chaffin et al. (20) California (USA) Prospective cohort study N = 24 cases
N = 242 controls
1959–1967 PE 30 56 (median) Cardiovascular risk
Callaway et al. (21) Australia Prospective cohort study N = 191 cases
N = 1921 controls
1981–1983 HDP 21 46.4 (mean) Essential chronic
hypertension
Cardiovascular risk
Melchiorre et al. (6) Europe (London,
UK)
Prospective longitudinal
case-control study
N = 64 cases
N = 78 controls
2008–2009 PE Two time points: 1
and 2 years
31 preterm PE
(median)
33 term PE
(median)
33.5 (median)
controls
Essential chronic
hypertension
Asymptomatic heart
failure (stage B)
Andersgaard et al. (22) Europe (Norway) Registry-based cohort study N = 901 cases
N = 9073 controls
NA PE 25.4 (median) 48.8 (median) Asymptomatic
atherosclerosis
Cardiovascular risk
Bhattacharya et al. (23) Europe (UK) Registry-based cohort study N = 10917 cases
N = 23937 controls
1950–2012 HDP NA NA Essential chronic
hypertension
Coronary heart disease
Cerebrovascular disease
Peripheral artery disease
Cardiovascular risk
Borna et al. (71) Asia (Iran) Retrospective case-control
study
N = 345 cases
N = 345 controls
NA HDP 32.2 (mean) cases
31.5
(mean) control
58.1 (mean) cases
55.9 (mean)
controls
Coronary heart disease
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TABLE 1 | Continued
References Demographic Design of the study Study population Year of pregnancy Complications of
pregnancy
Post-partum
follow-up time
in years
Age of the
women at the
assessment
in years
Cardiovascular
outcomes assessed
Gastrich et al. (72) North America
(USA)
Retrospective case-control
study
N = 302 cases
N = 864 controls
1994–2009 PE Within 16 NA Coronary heart disease
Cerebrovascular disease
Cardiovascular event
Drost et al. (24) Europe
(Netherlands)
Prospective case-control
study
N = 339 cases
N = 332 controls
1991–2007 PE 10 38.9 (mean) Essential chronic
hypertension
Cardiovascular risk
Fraser et al. (25) Europe (UK) Prospective cohort study N = 2172 cases 1991.1992 HDP 18 48 (mean) Cardiovascular risk
Ray et al. (73) North America
(Canada)
Retrospective cohort study N = 75242 cases
N = 1 055 522
controls
1992–2009 PE, HDP, PA 7.8 (median) 37.8 (mean) Heart failure C and
dysrhythmias
Skjaerven et al. (26) Europe (Norway) Prospective cohort study N = 34824 cases 1967–2009 PE 25 NA Coronary heart disease
Cerebrovascular disease
Cardiovascular risk
Cardiovascular event
Smith et al. (27) North America
(Canada)
Prospective longitudinal
cohort
N = 99 cases
N = 118 control
2003–2009 PE 1 time 1
3 time 2
30.3 (mean) time 1
30.5 (mean) time 2
Cardiovascular risk
Spaan et al. (28) Europe
(Netherlands)
Prospective longitudinal
Cohort
N = 683 cases 1996–2010 PE 0.66 31.4 (mean) Cardiovascular risk
Mangos et al. (29) Australia Prospective case control N = 66 cases
N = 35 controls
NA HDP PE: 3.8 (mean)
GH: 2.9 (mean)
Controls:
4.3 (mean)
PE: 37 (mean)
GH: 36 (mean)
Controls:
38 (mean)
Essential chronic
hypertension
Cardiovascular risk
Drost et al. (30) Europe
(Netherlands)
Longitudinal Cohort study N = 689 cases
N = 2703 controls
1987–2007 HDP Every 5 years 38.4 (mean) time 1
46.7 (mean) time 2
50.8 (mean) time 3
54.1 (mean) time 4
Essential chronic
hypertension
Cardiovascular risk
Hermes et al. (31) Europe
(Netherlands)
Prospective, case-control N = 94 cases
N = 300 controls
2005–2008 HDP 2.5 As the woman was
60 years old for
the extrapolation
at 10-year risk
Current age (34
years old) for
extrapolation at
30-year risk
Essential chronic
hypertension
Cardiovascular risk
Scholten et al. (32) Europe
(Netherlands)
Prospective Cohort study N = 1297 cases 2004–2010 PE 0.58 (median) 32 (median) Essential chronic
hypertension
Cardiovascular risk
(Continued)
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TABLE 1 | Continued
References Demographic Design of the study Study population Year of pregnancy Complications of
pregnancy
Post-partum
follow-up time
in years
Age of the
women at the
assessment
in years
Cardiovascular
outcomes assessed
Van Rijn et al. (33) Europe
(Netherlands)
Prospective cohort study N = 243 cases
N = 374 control
1994–2007 PE 0.75 (mean) 30.5 (mean) Cardiovascular risk
Kurabayashi et al. (34) Japan Cross–sectional N = 1219 cases
N = 9237 controls
2001–2007 HDP NA ≥ 45 at time of
survey
Essential chronic
hypertension
Nakimuli et al. (35) Uganda Prospective Cohort study N = 64 cases
N = 124 controls
2009–2011 PE, Eclampsia 0.25 27.3 (mean) cases
24 (mean) controls
Persistent hypertension 3
months after delivery
Tooher et al. (36) Australia Observational cohort study N = 7706 cases
N = 64113 controls
2006–2009 HDP NA ≥ 45 years age at
study
Essential chronic
hypertension
Cerebro-vascular disease
McDonald et al. (74) North American
(Canada)
Retrospective cohort study N = 109 cases
N = 218 controls
1986–1995 PE 20 (median) 49 (median) Asymptomatic
atherosclerosis
Watanabe et al. (75) Asia (Japan) Retrospective cohort study N = 101 cases
N = 1,084 controls
NA HDP NA 46.5 (mean) Essential chronic
hypertension
Barry et al. (76) North American
(USA)
Retrospective case-control
study
N = 49 cases
N = 22 controls
2014 PE >8 months 34 (mean) Essential chronic
hypertension
Peripheral artery disease
Hosaka et al. (37) Asia (Japan) Prospective cohort study N = 28 cases
N = 785 controls
1994–1998 HDP 7 (median) 37 (mean) Essential chronic
hypertension
Black et al. (38) North American
(California)
Prospective cohort study N = 5960 cases
N = 358 controls
2005–2010 HDP 1 (median) 28 (mean) Essential chronic
hypertension
Cain et al. (77) North American
(State of Florida)
Population-based
retrospective cohort study
N = 847 cases
N = 1854 controls
2004–2007 HDP, PA, PD, SGA 4.9 (median) 25 (median) Cardiovascular event
Ray et al. (78) North America
(Canada)
Population-based
retrospective cohort study
N = 362 cases
N = 1623 controls
Delivery was at
least 90 days
preceding the index
coronary artery
revascularization
date (1993–2012)
PE, HDP, PA 11.3 (mean) cases
14.2 (controls)
44.7 (mean)
controls
46.5 (mean)
controls
Death after coronary
artey revascularization
White et al. (36) North America
(USA)
Prospective, cohort study N = 40 cases
N = 40 controls
1976–1982 PE 30 (median) 59.5 (mean) Essential
chronic hypertension
Coronary heart disease
Behrens et al. (37) Europe
(Denmark)
Prospective cohort study N = 23 235 cases
N = 459.737 controls
1995–2012 (first
cohort)
1978–2012
(second cohort)
HDP 10 (mean), first
cohort
20 (mean), second
cohort
30 (median) Essential chronic
hypertension
Breetveld et al. (41) Netherlands Prospective longitudinal
cohort study,
N = 69 cases 2005–2007 PE 1 and 4 y
post-partum
32 (mean) at 1sr
assessment
35 (mean) at
2nd assessment
Asymptomatic heart
failure (stage B)
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TABLE 1 | Continued
References Demographic Design of the study Study population Year of pregnancy Complications of
pregnancy
Post-partum
follow-up time
in years
Age of the
women at the
assessment
in years
Cardiovascular
outcomes assessed
Facca et al. (79) South American
(Brazil)
Retrospective cohort study N = 25 cases
N = 60 controls
1976–2016 HDP 16 (mean) 46 (mean) Essential chronic
hypertension
Peripheral artery disease
Fatma et al. (72) Asia (India) Retrospective
case control study
N = 50 cases
N = 50 controls
NA PE NA 20–45 (range) Essential chronic
hypertension
Peripheral artery disease
Ghossein-Doha et al. (42) Netherlands Cross-sectional cohort
study
N = 107 cases
N = 41 controls
NA PE 4–10 36 (mean) cases
40 (mean) controls
Asymptomatic heart
failure (stage B)
Grandi et al. (43) Europe (UK) Population-based cohort
study
N = 5399 cases
N = 141349 controls
1990–2013 HDP 4.7 (median) 29.5 (mean) Essential chronic
hypertension
Cardiovascular event
Mito et al. (44) Asia (Japan) Prospective cohort study N = 25 cases
N = 746 controls
2003–2005 HDP 5 (median) 40.3 (mean) Essential chronic
hypertension
Orabona et al. (81) Europe (Italy) Retrospective case–control
study
N = 109 cases
N = 60 controls
2007–2013 PE 4 (median) 38 (median) Cardiac dysfunction and
remodeling
Tooher et al. (82) Australia Retrospective cohort study N = 4387 cases
N = 27262 controls
1980–1989 HDP 20 (median) 48 (median) Essential chronic
hypertension
Coronary heart disease
Cerebrovascular disease
Wang et al. (83) Asia (China) Retrospective cohort study N = 94 cases
N = 1167 controls
All GDM patients
2005–2009 HDP with GDM 2.29 (mean) 33 (mean) Essential chronic
hypertension
Benschop et al. (45) Europe
(Netherlands)
Prospective cohort N = 200 2011–2017 Severe PE 1 (median) 31.6 (mean) Essential chronic
hypertension
Bergen et al. (46) Europea
(Netherlands)
Prospective cohort study N = 300 cases
N = 4612 controls
NA HDP 6 (median) 30 (mean) Essential
chronic hypertension
Cardiac dysfunction and
remodeling
Bokslag et al. (84) Europe
(Netherlands)
Retrospective case control
study
N = 131 cases
N = 56 controls
1998–2005 Early onset PE 9–16 (range) 45 (mean) Essential chronic
hypertension
Asymptomatic heart
failure (stage B)
Peripheral artery disease
Breetveld et al. (47) Europe
(Netherlands)
Prospective case control
study
N = 67 cases
N = 37 controls
2009–2011 PE 5.3 (median) 36 (median) Asymptomatic heart
failure (stage B)
Peripheral artery disease
Chen et al. (85) Asia (Taiwan) Population–based
retrospective cohort study
N = 29.186 cases
N = 116.744 controls
2000–2013 HDP 5.72 (mean) NA Heart failure
Cho et al. (86) Asia (Korea) Retrospective observational
cohort study
N = 148 cases
N = 1762 controls
2004 PE 8 (mean) NA Essential chronic
hypertension
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TABLE 1 | Continued
References Demographic Design of the study Study population Year of pregnancy Complications of
pregnancy
Post-partum
follow-up time
in years
Age of the
women at the
assessment
in years
Cardiovascular
outcomes assessed
Clemmensen et al. (48) Europe
(Denmark)
Observational cohort study N = 53 cases
N = 40 controls
1998–2008 PE 12 (median) 41 (mean) Coronary flow velocity
reserve
Ditisheim et al. (49) European
(Switzerland)
Prospective cohort study N = 115 cases
N = 41 controls
2010–2013 PE 0.11–0.23 (range) 33.7 (mean) Essential chronic
hypertension
Dunietz et al. (87) North American
(USA)
Retrospective cohort study N = 301 cases
N = 366 controls
1998–2004 HDP 11 (mean) 38 (mean) Essential chronic
hypertension
Egeland et al. (50) Europe (Norway) Prospective cohort study N = 1480 cases
N = 58.547 controls
2004–2009 HDP, pre-gestational
DM, GDM, PD, FGR
7.1 (mean) NA Essential chronic
hypertension
Escouto et al. (51) Europe (UK) Prospective longitudinal
cohort study
N = 412 cases
N = 65 controls
2009–2013 HDP 0.13 (median) 29.6 (mean) Cardiovascular risk
Fossum et al. (88) Europe (Norway
Netherlands)
Population based
retrospective cohort study
N = 13.348 cases
N = 164.883 controls
1967–1998 HDP 18 (mean) 41 (mean) Essential chronic
hypertension
Grandi et al. (52) North American
(Canada)
Population-based
prospective cohort study
N = 5399 cases
N = 141,349 controls
1999–2015 HDP 5 (median) 29.5 (mean) Essential chronic
hypertension
Cardiovascular event
Hauspurg et al. (53) North American
(USA)
Prospective cohort study N = 61 cases
N = 254 controls
NA HDP 0.58 (mean) 23,9 (mean) Essential chronic
hypertension
Jarvie et al. (89) North American
(USA)
Retrospective cohort study N = 108.875 cases
N = 1.344.051controls
2004–2010 HDP 3 (median) 27.2 (mean) Acute myocardial
infarction
Stroke
Heart failure
Kuo et al. (90) Asia (Taiwan) Retrospective longitudinal
study
N = 1295 cases
N = 5180 controls
1996–2010 PE or Eclampsia 9.8 (median) 30 (median) Essential chronic
hypertension
Heart failure
Cerebro-vascular disease
Markovitz et al. (54) Europe (Norway) Prospective cohort study N = 7936 cases
N = 18608 controls
1967–2008 HDP, SGA, PD 8.2 (median) 52 (median) Cardiovascular event
Riise et al. (55) Europe (Norway) Prospective cohort study N = 41 434 cases
N = 576155 controls
1980–2009 HDP, SGA, PD 14.3 (median) NA Coronary heart disease
Cerebro-vascular disease
Cardiovascular event
Soma-Pillay et al. (56) Africa (South
African)
Prospective, case control
study
N = 96 cases
N = 45 controls
2013–2015 PE 1 (median) 28 (mean) Cardiac dysfunction and
remodeling
Stuart et al. (57) North American
(USA)
Observational cohort study N = 5386 cases
N = 53274 controls
1989–2009 HDP 28 (median) 55 (mean) Essential chronic
hypertension
Theilen et al. (91) North American
(USA)
Retrospective cohort study N = 57,384 cases
N = 114,768 controls
N = 4722 cases
deceased
N = 7172
controls deceased
1939–2012 HDP cause of death for
deaths occurring
at age ≤50 years
vs. age >50 years
NA (mean age at
childbirth 26)
Coronary heart disease
Cerebro-vascular disease
(Continued)
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TABLE 1 | Continued
References Demographic Design of the study Study population Year of pregnancy Complications of
pregnancy
Post-partum
follow-up time
in years
Age of the
women at the
assessment
in years
Cardiovascular
outcomes assessed
Timpka et al. (58) Europe
(Sweden)
Prospective cohort study Cohort 1
N = 952 cases
N = 6600 controls
Cohort 2
N = 658 cases
N = 4702 controls
1955–1997 HDP, LBW offspring
(<2500g)
20 (median) 50 (mean)
Cohort 1
60 (mean)
Cohort 2
Cardiovascular risk
Zoet et al. (59) Europe
(Netherlands)
Multicenter, prospective
cohort study
N = 164 Cases
N = 387 Controls
NA HDP 10–20 (range) 48.4 (mean) Asymptomatic
atherosclerosis
Akhter et al. (60) Europe
(Sweden)
Case control study N = 23 cases
N = 35 controls
2008–2011 PE 7 39 (median) Asymptomatic
atherosclerosis
Clemmensen et al. (61) Europe
(Denmark)
Case control study N = 49 cases
N = 39 controls
1998–2008 PE 12 (median) 41.5 (mean) Coronary heart disease
Haug et al. (62) Europe (Norway) Prospective cohort study N = 2119 cases
N = 21766 controls
1984–2008 HDP 18 (median) 49 (mean) Cerebro-vascular disease
Coronary heart disease
Hromadnikova et al. (63) Europe (Czech
Republic)
Prospective cohort study N = 186 cases
N = 90 controls
2007–2013 HDP, FGR 5.4 (mean) 38 (median) Essential chronic
hypertension
Cardiovascular event
Groenhof et al. (64) Europe
(Netherlands)
Population-based cohort
study
N = 1005 cases
N = 1811 controls
1997–2012 HDP 15 (median) 48.6 (median) Essential chronic
hypertension
Orabona et al. (92) Europe (Italy) Retrospective Case control
study
N = 60 cases
N = 30 controls
2009–2013 PE 2.35 (mean) 37 (mean) Cardiac dysfunction and
remodeling
Riise et al. (65) Europe (Norway) Population-based
prospective cohort study
N = 1246 cases
N = 18829 controls
1980–2003 HDP 10.7 (mean) 37.2 (mean) Cerebro-vascular disease
Coronary heart disease
Cardiovascular risk
Cardiovascular event
Sia et al. (93) North American
(Canada)
Retrospective case control
study
N = 244 cases
(Coronary artery
disease)
N = 246 controls
NA HDP NA NA Coronary heart disease
Timokhina et al. (66) Russia Prospective observational
case-control
N = 90 cases
N = 55 controls
2012–2015 PE 0,17 (mean) time 1
0,5 (mean) time 2
31,7 (median) Cardiac dysfunction and
remodeling
NA, not available; PE, pre-eclampsia; FGR, fetal growth restriction; HDP, hypertensive disorders of pregnancy; SGA, small for gestational age; LBW, low birth weigth; PD, preterm delivery; PA, placental abruption; GDM, gestational
diabetes mellitus.
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GH having an aOR of 1.61 (95%CI 1.09–2.39)” (53). Moreover,
“women who had PE showed an aOR of 3.23 (95%CI 1.56–6.68) of
hypertension with abnormal biomarkers later in life” (53). Other
authors found that early vs. late onset PE had a higher risk of
developing chronic hypertension late in life (3, 6). Furthermore,
Tooher et al. found that “the severity of hypertension in pregnancy
tracked with increased risk of future hypertension” (82), while
subsequent pregnancies did not seem to confound a first episode
of HDP and later CVD (82). Moreover, in a recent meta-analysis.
Brouwers et al. have demonstrated that subjects with recurrent PE
had a higher risk of future essential hypertension than formerly
PE women with a successive unaffected gestation (RR 2.3, 95% CI
1.9 to 2.9) (94). The relation between HDP, future occurrence of
essential hypertension and other pre-pregnancy CV risk has also
been assessed to try and isolate the effect of pregnancy on this
outcome. On this subject, Cho et al. found that the development
of high blood pressure in pre-eclamptic women was related to
pre-pregnancy factors such as family history, obesity and high
blood pressure (86). This latter result is only partially confirmed
by Mito et al. who found that women who had HDP presented
an higher risk of developing high blood pressure 5 years after
the index pregnancy “even after adjusting for confounding factors
such as age, body mass index, family history of hypertension
and salt intake (odds ratio 7.1, 95% CI, 2.0–25.6, P < 0.003)”
(44). Bergen et al. also found that although adjustment for
BMI attenuate the relationship between HDP in childbirth age
and future chronic hypertension by 65%, however it remained
significant (46). In contrast, Wang et al. (83) found that “history
of HDP had a four-fold multivariable-adjusted risk (95% CI 2.29–
6.24) of hypertension,” while no influence was established by pre-
conceptional anthropometric indices on the incidence of high
blood pressure after delivery (83). A stratification of the risk of
hypertension depending on the year post-partum after a gestation
affected by HDP has also been addressed in several studies.
Interestingly, Behrens et al. found that the risk of hypertension
associated with HDP was high closely after a complicated
gestation and continued for more than two decades (40). About
30% of subjects who suffered from a HDP may develop high
blood pressure within 10 years after a complicated gestation; “this
risk was 12- to 25-fold higher in the first year, up to 10-fold in
10 year, 2-fold after 20 year” (40). In term of number of women
to be screened to detect one case of essential hypertension,
Groenhof et al. found that at the age of 35, 9 women with HDP
needed to be screened to detect 1 clinically relevant hypertension
(64). The risk of developing essential high blood pressure
after a gestation affected by HDP has also been correlated
to the presence of specific echocardiographic findings (6).
Specifically, Melchiorre et al. found that formerly pre-eclamptic
normotensive women with moderate-severe echocardiographic
left ventricle (LV) anomalies identified at 1 year after delivery
were more likely to develop high blood pressure at 2 years
after delivery (50%) in comparison to those with normal LV
function/geometry or mild LV dysfunction/remodeling (3.5%)
with a relative risk of chronic high blood pressure in women
with LV moderate-severe abnormalities of 14.5 (95% CI 5.14
to 40.89, P < 0.001) (6). In the above mentioned study
the severity of LV dysfunction and hypertrophy was graded
according to the European Association and American Society
of Echocardiography guidelines (EAE/ASE) (95, 96). Specifically:
LV remodeling-hypertrophy was defined mild, moderate or
severe if LV mass/body surface area (g/m2) was between 96 and
108, 109 and 121 or ≥122, respectively; LV diastolic dysfunction
was defined as mild in the case of impaired myocardial relaxation
pattern (grade I), moderate in the case of pseudo-normal filling
pattern (grade II) or severe if restrictive filling was seen (grade
III) accordingly to the EAA/ASE diagnostic algorithms for the
diagnosis and grading of diastolic dysfunction (96). LV systolic
function was graded based on the ejection fraction value (EF) as
mildly, moderately or severely abnormal if EF (%) was between
45 and 54, 30 and 44 or <30. This finding has been confirmed by
the subsequent echocardiographic studies (97).
Peripheral Artery Disease
HDP have also been associated with increased risk of developing
peripheral artery disease (98).
“Peripheral artery disease” (PAD) refers to an abnormal
narrowing of arteries other than those that supply
the heart or brain, commonly caused by atherosclerosis. PAD
most commonly affects the lower extremities vessels (99).
“Depending on the degree of narrowing at each vascular site, a
range of severity of symptoms may occur, while many patients will
remain asymptomatic throughout their life. Occasionally acute
events occur, often associated with thrombosis and/or embolism
and/or occlusion of a major artery” (ESC task force PAD) (99).
Ray et al. in their population-based retrospective cohort study
on more than one million women, assessed the association
between HDP, placental abruption and infarction (defined as
maternal placental syndromes) and the occurrence of hospital
admission or revascularization for PAD at least 90 days after the
delivery discharge date (67). They found that the risk of PAD
in women who suffered from maternal placental syndromes was
3.8 (2.4–5.9) higher than that of women who had an uneventful
pregnancy (67). The future risk of PAD remained significant
after adjusting for traditional risk factors for CVD, including
maternal smoking and metabolic syndrome (adjusted risk 3: 1.9–
4.8) and was highest in women who had HDP in combination
with fetal compromise, compared to women who had not (67).
Lykke et al. also found that severe PE increased the risk of
subsequent thromboembolism of 1.9-fold (range 1.35–2.70) and
that the relationship was “dose-dependent” (16). Subsequent
studies confirmed the increased risk of PAD in women who
had HDP.
Asymptomatic Atherosclerosis
Several studies have addressed the issue of the relationship
between HDP and asymptomatic/pre-clinical atherosclerosis
(Table 1). “Asymptomatic atherosclerosis” refers to the
coronary/carotid artery inflammatory disease while the
condition is still in a subclinical stage but the presence of
atherosclerosis can be well-identified and quantified by several
invasive and non-invasive techniques, including coronary
angiography, ultrasonography, computed tomography, and
magnetic resonance imaging (100). In a prospective cohort
study, “a history of PE was associated with an increased risk of
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coronary artery calcifications (CAC) >30 years after the index
pregnancy”, even after controlling individually for traditional
risk factors although this association was not more significant
when corrected for current hypertension (39). Specifically, the
authors found that the odds of presenting a higher CAC score
was 3.54 (CI: 1.39–9.02) times greater in formerly pre-eclamptic
women compared to women who did not develop PE without
adjustments and it was 2.61 (CI: 0.9–7.14) times greater after
correction for current high blood pressure (39). On the contrary,
the association between CAC score and history of PE remained
significant after adjusting for body mass index alone (odds: 3.20;
CI: 1.21–8.49) (39). It has been also shown that one third of
subjects who had PE express features of coronary atherosclerosis
on vascular computed tomography imaging as compared to one
fifth of women from the reference group imaging and this result
is manifest as early as at age 45–55 years when women are on
average 16 ± 6 years postpartum (59). In contrast, a prospective
case-control study showed that the “average maximum carotid
intima media thickness (CIMT) was similar among women
with vs. without PE (0.831mm vs. 0.817, p = 0.38), and PE
was not a significant predictor of CIMT in a multiple linear
regression model (p = 0.63), despite more electrocardiograms
compatible with coronary disease” (74). Specifically, the authors
of the above mentioned prospective study defined “abnormal
electrocardiograms” the ones with at least one of the following:
the presence of Q waves/isolated infarct, new left bundle branch
block, ST elevation, ST depression, T wave inversion (74).
The conventional measurement of common carotid artery
intima-media thickness (CCA-IMT) does not represent this
(60) as opposed to measurement of the individual CCA intima
and media thicknesses which visibly reflect augmented vascular
risk (60).
Asymptomatic Heart Failure
Several studies assessed the relationship between HDP and
the subsequent development of asymptomatic (stage B) or
symptomatic (stage C) heart failure (97, 101). The American
Heart Association and American College of Cardiologists define
asymptomatic stage B heart failure as any subject being affected
by LV hypertrophy or dysfunction (102). At this regard, it
should be taken into account that several echocardiographic
studies in pregnancy already showed a state biventricular
dysfunction and hypertrophy, low cardiac output and high total
vascular resistancein pre-eclamptic women in pregnancy vs.
normotensive matched pregnant controls (3–5) A subsequent
prospective longitudinal follow-up study of PE vs. controls
assessed at 1 and 2 years post-partum showed, integrating
conventional echocardiography, color and pulsed wave tissue
Doppler, strain and strain rate techniques, that the prevalence
of asymptomatic stage B heart failure (HF-B) at one year
postpartum follow-up was significantly higher in preterm vs.
term preeclampsia and controls (70 vs. 25 vs. 10%, respectively;
p < 0.001), but not in term preeclampsia vs. controls (6).
Similarly, moderate-severe left ventricular (LV) dysfunction and
remodeling (according to the EAE/ASE diagnosis and grading
of abnormal LV structure and function) were significantly more
prevalent in formerly preterm PE women compared with those
who had term preeclampsia and controls (3, 6). Similarly, Soma-
Pillay et al. showed that women with early onset PE had an
increased risk of diastolic dysfunction at 1 year post-partum
(RR 3.41, 95% CI: 1.11–10.5, p = 0.04) and regardless of
the presence of chronic hypertension (56). Breetveld et al. in
their prospective longitudinal cohort study confirmed that the
prevalence of HF-B was consistently high (1 in 4) amongst
formerly PE women at 1 and 4 years postpartum (41). Moreover,
in a subsequent observational case-control study, he confirmed
that the prevalence of HF-B in formerly PE women was three-
fold higher than that detected for healthy parous controls (25
vs. 8%, P < 0.05) at more than 4 years post-partum (47). The
increased risk of asymptomatic HF in formerly PE women was
further confirmed by Ghossein-Doha et al. who also found that
prehypertension increased this risk significantly, while metabolic
syndrome elements did not (42). Orabona et al. conducted a
prospective study on hemolysis, elevated liver enzymes, and
a low platelet count syndrome (HELLP) and PE women and
also documented in both HELLP and PE groups a higher
prevalence of LV concentric remodeling, diastolic dysfunction
and reduced LV ejection fraction at 6 months to 4 years post-
partum vs. matched healthy controls (81). Bokslag et.al. also
found that history of PE predisposes in middle age, 9–16 years
after pregnancy, to worse LV diastolic function, which could
increase the likelihood of later heart failure with preserved
ejection fraction (84).
Heart Failure
Several large registry-based studies addressed the issue of
the relationship between HDP and symptomatic heart failure.
Specifically, in a retrospective registry-cohort study on short term
cardiovascular outcome in women who had HDP, Jarvie et al.
scrutinized all hospital-based deliveries in Florida from 2004 to
2010 and following cardiovascular (CV), non-CV and any second
hospitalization to any Florida hospital within 36 months of
index delivery excluding subsequent deliveries (89). They found
that “women with HDP had twice the risk of CV readmission
within 3 years of delivery (6.4 vs. 2.5/1,000 deliveries; P < 0.001),
with higher rates among African American women. Heart failure
was the most common reason for CV readmission accounting for
78.6% of all CV readmissions and 84.4% of CV readmissions
in women with HDP” (89). Furthermore, in a retrospective
longitudinal registry study on long term outcome in women who
had HDP, Kuo et. al. using National Health Insurance Research
Database, found that formerly PE and eclamptic women were
at increased risks of congestive heart failure (hazard ratio 9.1,
and 7.4, respectively) with a drastic increase of congestive heart
failure occurrence at 3 and 10 years since the index pregnancy
(90). Similarly, Chen et al. in a retrospective cohort study found
that heart failure incidence was greater in the HDP group than
controls (9.83 vs. 1.67 per 10,000 person-years), was more likely
to develop within 5 years and that severe or recurrent HDP had a
greater risk (85).
Coronary Heart Disease
Numerous studies have assessed the relationship between
HDP and subsequent coronary heart disease (Table 1).
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FIGURE 1 | Incidence data (I) of ischemic heart disease (IHD), stroke, venous
thromboembolism (VTE) and death from any cause in formerly PE women (PE)
vs. women who had an uneventful pregnancy (UP). Modified from
Bellamy et al. (1).
FIGURE 2 | Incidence data (I) of future risk of major coronary events and
cardiovascular mortality in formerly PE women (PE) vs. women who had an
uneventful pregnancy (UP), showing the dose effect response of specific
characteristics of pregnancy with preeclamspia such as small for gestational
age (SGA) and preterm delivery (PD). Modified from Riise et al. (55).
“Coronary artery disease” refers to the clinical manifestations of
atherosclerosis and comprehends a range of diseases that result
from atheromatous change in coronary vessels. Specifically, it
includes the following: (stable and unstable) angina pectoris,
myocardial infarction, sudden cardiac death (100).
Interestingly, a previous study on cardiac function and
structure in pre-eclamptic women showed the presence of
echocardiographic findings suggestive of segmental myocardial
ischemia and fibrosis (4–6). Specifically, significantly higher
prevalence of basal septal post-systolic shortening, identified
by Color Tissue Doppler-derived strain analysis, associated to
septal bugling and segmental abnormal myocardial strain and
strain rate indices were found in a minority of pre-eclamptic
women with severe disease vs. normotensive pregnant controls
FIGURE 3 | Incidence data (I) of ischemic heart disease (IHD), stroke and
heart failure in recurrent preeclamspia women (recurrent PE) vs. women
affected by a single pregnancy with PE and subsequent normal pregnancy
(not recurrent PE) showing the “dose effect” response of recurrent
preeclampsia. Modified from Brouwers et al. (94).
and these echocardiographic findings have been associated in
human autopsy studies and in animal in vitro studies to regional
myocardial ischemia (4–6). Not surprising the prevalence of
ischemic heart disease in formerly PE women is significantly
higher than in parous controls with an uneventful pregnancy
(1, 101) (Figure 1). As well as it has been demonstrated in
chronic hypertension, this higher risk of developing coronary
artery disease in women who had HDP show a “dose dependent
effect,”, being higher in the presence of a more severe disease in
pregnancy, in the case of associated fetal growth abnormalities
and iatrogenic preterm birth and if PE recurred in subsequent
pregnancies (55, 94) (Figures 2, 3). Moreover, the association was
not explained by adjustment for confounding variables, although
it was attenuated by the presence of other CV risk factors
(55, 94). In particular, Tooher et. al. directed a retrospective
cohort study on all subjects who delivered at a tertiary hospital
in Sydney between the years 1980 and 1989 (n = 31,656) of
whom 4,387 had HDP (82). The whole cohort were studied
for linkage analysis to future CVDs and he found that the
formerly HDP women were at increased risk of admission for
future CVD vs. normotensive parous controls (OR 2.1; 95%
CI, 1.7–2.6) (82). The median time from the index gestation
to the occurrence of CVD was 20 years with a range of 3–29
years (82). Another study demonstrated that among a cohort
of subjects with acute coronary syndrome, positive history of
pregnancy adverse outcome was related with more severe disease
and worse outcome (103). In particular, at presentation with
acute coronary syndrome, women who had PE were younger
and had more conventional CV risk factors such as essential
high blood pressure and an increased soluble fms-like tyrosine
kinase:placental growth factor ratio compared to women who
had uncomplicated gestation (103). There was also an increased
risk of recurrence of acute coronary syndrome at 1 year in women
with previous PE (hazard ratio, 6.8) (103). Moreover, women
with≥2 complicated gestation had an increased cardiacmortality
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risk as shown by Theilen et al. (aHR= 3.3, 95% CI 2–5.4) (91).
A large registry-study in Norway also revealed that GH was
associated with increased risk of subsequent cardiovascular
disease and the highest risk was noticed when GH was combined
with fetal growth abnormalities infants and/or preterm delivery
(65). Subsequent studies confirmed this association between
HDP and increased risk of myocardial infarction at 40–70y with
an HR of 2.08 for formerly PE women and 1.56 or formerly
GH women (62). Furthermore, an interesting study on the
relationship between coronary flow velocity reserve (CFVR) by
Doppler echocardiography and previous HDP found that the
mean coronary flow velocity reserve was significantly impaired
in the early-onset than in the late-onset PE and in the control
group with a positive relation between gestational age at PE
diagnosis and coronary flow velocity reserve which notable
persisted significant after adjustment for conventional cardiac
risk factors such as bodymass index, blood pressure, and glycated
hemoglobin (61).
Cerebro-Vascular Disease
There is general agreement on the link between HDP and
subsequent risk of stroke (Table 1). It has been demonstrated that
not only PE/Eclampsia increase the risk of cerebrovascular events
with an HR of 10.7 (p < 0.0001) (90), but Haug et al. (62) and
Tooher et al. (82) is also associated with increased risk of stroke.
A large population-based study found that formerly GH women
had a 1.3-fold (95% CI 0.9–1.7) higher risk of suffering from
cerebrovascular disease compared with parous controls with
uncomplicated gestation (55). In general, HDP women seem to
have an increased risk of cerebrovascular events (HR 1.47, 1.15–
1.87) at 40–70 years (62). Moreover, no significant difference
was found in relation to the use of antihypertensive drugs or
the duration of HDP and subsequent hospitalization for stroke
(82). Again, there seems to be a “dose dependent” effect of HPD
on cerebrovascular mortality, with women who had more than
two complicated gestation showing an increased mortality from
stroke (aHR= 5.10), as well as the other causes of cardiovascular
mortality, compared to parous women who had only 1 or 0
pregnancies complicated by HDP (1, 91, 94) (Figures 1, 3).
CONCLUSIONS
HDP is associated with increased risk of cardiovascular
diseases later in life. This is not surprising as several studies
have demonstrated that women with PE present in a state
of cardiac dysfunction, ventricular hypertrophy and indirect
echocardiographic signs of localized myocardial ischemia and
fibrosis (103, 104). Moreover, the structural and functional
cardiovascular changes do not completely reverse at 1 year
post-partum and are known to have strong prognostic value
for future cardiovascular morbidity and mortality in non-
pregnant subjects (104). The relationship is stronger in the
case of severe or early-onset HDP, concomitant fetal growth
disorders, need for iatrogenic preterm delivery and recurrent
HDP. Adjustments for confounders (such as family history of
cardiovascular diseases, high BMI, hypertension, diabetes, and
dyslipidemia) do not eliminate, but attenuate this relationship.
The underlying mechanisms have not been fully elucidated, but
a concomitance of pre-pregnancy predisposition to increased
risk of cardiovascular disease and a direct effect of pregnancy
on the cardiovascular system may play a role in determining
this excess of cardiovascular morbidity and mortality in
women who experienced PE and GH in pregnancy. Guidelines
regarding timing and extent of cardiovascular follow-up as
well as strategies of prevention after HDP are lacking, but
it is reasonable to recommend that screening should be
started as early as 1 year after delivery and should primarily
include awareness of the women of their future increased
CV risk and lifestyle modifications with weight control,
smoking cessation, healthy diet, and daily exercise. Future
studies should address the issue of a structured screening for
cardiovascular disease and the impact of timely preventive
intervention in improving cardiovascular health in this group of
young women.
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